![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
CytoDyn and Chiral Pharma will work together to register leronlimab (PRO 140) for potential approval from the local Food and Drug Administration to treat patients with COVID-19 in the Philippines.
Lead Product(s): Leronlimab
Therapeutic Area: Infections and Infectious Diseases Product Name: PRO 140
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: CytoDyn
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 12, 2020